CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 421 enrolled
Drug / intervention
Benralizumab 100 mg +1 morebiological
Likely dose
Benralizumab 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01227278
NCT01227278Phase 2Completed
CompareCT.gov

A Phase 2a, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI-563 in Subjects With Moderate-to-severe Chronic Obstructive Pulmonary Disease and Sputum Eosinophilia

MedImmune LLC·interventional·Posted Oct 25, 2010·Updated Oct 5, 2016

In Brief

A Phase 2 clinical trial evaluating Placebo and Benralizumab 100 mg for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 421 participants across 31 sites in 7 countries.

Detailed Summary

To evaluate the effect of the drug in moderate to severe Chronic Obstructive Pulmonary Disease (COPD) in Adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesCanada, Denmark, Germany, Poland, Spain, United Kingdom, United States
CollaboratorsAstraZeneca

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 25, 2010
Enrollment StartNov 1, 2010
Primary CompletionJan 1, 2013
Study CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 15.7 years ago

Interventions

Placeboother

Placebo matched to benralizumab (MEDI-563) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).

Benralizumab 100 mgbiological

Benralizumab (MEDI-563) 100 mg injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).